Market Research Logo

Global Protein Therapeutics Market 2017-2021

Global Protein Therapeutics Market 2017-2021

About Protein Therapeutics

Therapeutic proteins are used to effectively treat a wide array of diseases such as protein deficiency diseases; chronic diseases such as cancer, rheumatoid arthritis (RA), ankylosing spondylitis, diabetes; infections such as human immunodeficiency virus (HIV), hepatitis A, hepatitis B, and hepatitis C; and other medical conditions such as genetic disorders, anemia cases related to kidney dialysis, and cancer-related anemia. Therapeutic proteins mostly consist of recombinant forms of naturally occurring proteins.

Technavio’s analysts forecast the global protein therapeutics market to grow at a CAGR of 7.86% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global protein therapeutics market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and biosimilar drugs used for the treatment of various diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report Global Protein Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novo Nordisk
Other prominent vendors
  • Anhui Anke Biotechnology (Group)
  • AstraZeneca
  • Baxter International
  • Biocon
  • Biodel
  • BioGenomics
  • Biopartners
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celltrion
  • Chugai Pharmaceutical
  • Diamyd Medical
  • Diasome Pharmaceuticals
  • DiaVacs
  • Dynavax Technologies
  • Eli Lilly
  • Ferring Pharmaceuticals
  • Generex Biotechnology
  • GeneScience Pharmaceuticals
  • Hualan Biological Engineering
  • Intas Pharmaceuticals
  • Ipsen
  • JCR Pharmaceuticals
  • Kyowa Hakko Kirin
  • Lexicon Pharmaceuticals
  • LG Life Sciences
  • MacroGenics
  • MannKind
  • Oramed Pharmaceuticals
  • Osiris Therapeutics
  • Pfizer
  • Sandoz International
  • Sanofi
  • Teva Pharmaceutical Industries
  • Thermalin Diabetes
  • Tolerion
  • Wockhardt
  • XOMA
Market driver
  • Increased demand for mAbs
  • For a full, detailed list, view our report
Market challenge
  • Complexities in manufacturing, storage conditions, distribution policies, and high cost
  • For a full, detailed list, view our report
Market trend
  • Emergence of next-generation biologics
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Protein Therapeutics Market 2017-2021

Technavio recognizes the following companies as the key players in the global protein therapeutics market: AbbVie, Amgen, F. Hoffmann-La Roche, Johnson & Johnson, Merck, and Novo Nordisk.

Other Prominent Vendors in the market are: Anhui Anke Biotechnology, AstraZeneca, Baxter International, Biocon, Biodel, BioGenomics, Biopartners, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Chugai Pharmaceutical, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Dynavax Technologies, Eli Lilly, Ferring Pharmaceuticals, Generex Biotechnology, GeneScience Pharmaceuticals, Hualan Biological Engineering, Intas Pharmaceuticals, Ipsen, JCR Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, LG Life Sciences, MacroGenics, MannKind, Oramed Pharmaceuticals, Osiris Therapeutics, Pfizer, Sandoz International, Sanofi, Teva Pharmaceutical Industries, Thermalin Diabetes, Tolerion, Wockhardt, and XOMA.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is emergence of next-generation biologics. Next-generation biologics market is evolving at a rapid pace. Although most of the next-generation biologics are the improvised versions of existing first-generation drugs, they are slated to achieve wider acceptance attributed to their reduced immunogenicity primarily.”

According to the report, one of the major drivers for this market is increased demand for mAbs. Monoclonal antibodies represent a major segment of the global protein therapeutics market. The understanding of diseases at the molecular level increases the development and use of mAbs in their treatment. These antibodies have a high affinity toward specific disease cells and areas that need to be treated. There is a remarkable increase in the use of mAbs in various therapies such as radioimmunotherapy and antibody-directed enzyme prodrug therapy.

Further, the report states that one of the major factors hindering the growth of this market is complexities in manufacturing, storage conditions, distribution policies, and high cost. Unlike small molecule drugs, proteins are prepared from living organisms. Hence, the manufacturing process involved is very complex and time-consuming. The process involves steps such as fermentation, clarification, separation, and purification. The process of separation is also difficult as different molecules differ slightly from each other. The purification process is also lengthy, and the risk of contamination is high as the drug is produced in the biological medium.

Companies Mentioned

AbbVie, Amgen, F. Hoffmann-La Roche, Johnson & Johnson, Merck, Novo Nordisk, Anhui Anke Biotechnology, AstraZeneca, Baxter International, Biocon, Biodel, BioGenomics, Biopartners, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Chugai Pharmaceutical, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Dynavax Technologies, Eli Lilly, Ferring Pharmaceuticals, Generex Biotechnology, GeneScience Pharmaceuticals, Hualan Biological Engineering, Intas Pharmaceuticals, Ipsen, JCR Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, LG Life Sciences, MacroGenics, MannKind, Oramed Pharmaceuticals, Osiris Therapeutics, Pfizer, Sandoz International, Sanofi, Teva Pharmaceutical Industries, Thermalin Diabetes, Tolerion, Wockhardt, XOMA.

  • Executive summary
  • Scope of the report
    • Market overview
    • Assumptions
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Highlights
  • Market landscape
    • Market overview
      • Table Overview of protein therapeutics market 2016-2021
      • Table Key strategies in global protein therapeutics market
      • Table Global protein therapeutics market snapshot: Developed and emerging markets 2015
      • Table Global protein therapeutics market 2016-2021 ($ billions)
      • Table Patent expirations of major biologics 2000-2030
      • Table Impact of factors affecting the market 2016 and 2021
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by product type
    • Table Segmentation of global protein therapeutics market by product type
    • Table Market share of global protein therapeutics market by product type
    • Global mAbs market
      • Table Overview of global mAbs market
      • Table Annual treatment cost per patient for various drugs 2015
      • Table Global mAbs market: Present and future scenario
      • Table Global mAbs market 2016-2021 ($ billions)
      • Table Opportunity analysis of global mAbs market
      • Table Year-over-year (YoY) sales comparison of mAbs 2013-2015 ($ billions)
    • Global human insulin market
      • Table Market overview of human insulin
      • Table Global human insulin market 2016-2021 ($ billions)
      • Table Factors affecting global human insulin market
      • Table Opportunity analysis of global human insulin market
      • Table Revenues from the sales of top five products in insulin market 2013-2015 ($ billions)
    • Global clotting factors market
      • Table Market overview of clotting factors
      • Table Global clotting factors market 2016-2021 ($ billions)
      • Table Opportunity analysis of global clotting factors market
    • Global EPO market
      • Table Market overview of EPO
      • Table Global EPO market 2016-2021 ($ billions)
      • Table Globally approved EPO biosimilars
      • Table Opportunity analysis of global EPO market
    • Global human growth hormone market
      • Table Market overview of human growth hormone
      • Table Global human growth hormone market 2016-2021 ($ billions)
      • Table Opportunity analysis of global human growth hormone market
  • Market segmentation by therapy area
    • Table Segmentation of global protein therapeutics market by therapy area
    • Metabolic and endocrine disorders
    • Hematopoiesis
    • Fertility
    • Cancer
    • Autoimmune diseases
    • Infectious diseases
    • Protein vaccine
  • Market segmentation by protein function
    • Table Segmentation of global protein therapeutics market by protein function
    • Enzymatic and regulatory activity
    • Special targeting activity
    • Vaccines
    • Protein diagnostics
  • Geographical segmentation
    • Table Global protein therapeutics market: Segmentation by geography (2016-2021)
    • Table Global protein therapeutics market segmentation by region: Market growth lifecycle analysis 2016
    • Protein therapeutics market in Americas
      • Table Overview of protein therapeutics market in Americas
      • Table Protein therapeutics market in Americas 2016-2021 ($ billions)
      • Table Protein therapeutics market in Americas: Opportunity analysis
    • Protein therapeutics market in EMEA
      • Table Overview of protein therapeutics market in EMEA
      • Table Protein therapeutics market in EMEA 2016-2021 ($ billions)
      • Table Protein therapeutics market in EMEA: Opportunity analysis
    • Protein therapeutics market in APAC
      • Table Overview of protein therapeutics market in APAC
      • Table Protein therapeutics market in APAC 2016-2021 ($ billions)
      • Table Protein therapeutics market in APAC: Opportunity analysis
  • Market drivers
    • Increased demand for mAbs
      • Table mAb approvals by the US FDA and EMA 2010-2015
    • Development of novel therapies using innovative technologies
      • Table Advances in ADCs technology
      • Table Few of other technologies used in protein therapeutics
    • Availability of favorable reimbursement policies
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Complexities in manufacturing, storage conditions, distribution policies, and high cost
    • Complicated regulatory framework
      • Table Approval process of biologicals versus biosimilars via Public Health Service Act (PHSA) in US
    • Alternate therapies loom large
      • Table Few of CAM therapies used for autoimmune and inflammatory diseases
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Emergence of next-generation biologics
      • Table Overview of next-generation antibodies
      • Table Oral insulin pipeline portfolio
    • Advent of biosimilars expected to improve the treatment rates
      • Table Few of the biosimilars under development
    • Strategic alliances further boost the R&D efforts
      • Table Key deals in global protein therapeutics market
  • Vendor landscape
    • Competitive scenario
      • Table Market presence of vendors in various therapy areas 2015
    • Market share analysis 2016
      • Table Competitive assessment of vendors
      • Table Geographical presence of key vendors
    • Other prominent vendors
  • Key vendor analysis
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Profile
      • Table F. Hoffmann-La Roche: Strength assessment
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table F. Hoffmann-La Roche: Opportunity assessment
    • Novo Nordisk
      • Table Novo Nordisk: Profile
      • Table Novo Nordisk: Strength assessment
      • Table Novo Nordisk: Strategy assessment
      • Table Novo Nordisk: Opportunity assessment
    • Amgen
      • Table Amgen: Profile
      • Table Amgen: Strength assessment
      • Table Amgen strategy assessment
      • Table Amgen: Opportunity assessment
    • AbbVie
      • Table AbbVie: Profile
      • Table AbbVie: Strength assessment
      • Table AbbVie: Strategy assessment
      • Table AbbVie: Opportunity assessment
    • Johnson & Johnson
      • Table Johnson & Johnson: Profile
      • Table Johnson & Johnson: Strength assessment
      • Table Johnson & Johnson: Strategy assessment
      • Table Johnson & Johnson: Opportunity assessment
    • Merck
      • Table Merck: Profile
      • Table Merck: Strength assessment
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report